mercoledì, 25 novembre 2020
Medinews
24 Novembre 2017

EU Approves Abiraterone for Newly Diagnosed Hormone-Sensitive Prostate Cancer

November 20, 2017 – The European Commission (EC) has approved abiraterone acetate in combination with prednisone/prednisolone for the treatment of adult men with newly-diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT). Janssen Biotech announced the commission’s decision in a press release. This move by the EC follows a recommendation issued in October from … (leggi tutto)

TORNA INDIETRO